Shielding against radiation will not only help people survive nuclear fallout but also improve health outcomes for cancer ...
Researchers propose that CNDP2-mediated cooperation can be an effective and specific target for cancer treatment.
Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...
In a paper published in National Science Review, an international team of scientists report a coordination nanomedicine ...
Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.
A guardian molecule ensures that liver cells do not lose their identity. This has been discovered by researchers from the German Cancer Research Center (DKFZ), the Hector Institute für Translational ...
Auron Therapeutics has raised a $27 million Series B financing that it will use to initiate clinical development of its lead experimental drug, AUTX-703, in blood cancers.
CIRBP Family, Tumors, Molecular Mechanisms, RNA-Binding Proteins, Cellular Stress Share and Cite: Cai, Y. , Wang, T. and Zhan ...
Cancer cells cripple immune cells by donating their damaged mitochondria, hindering the immune response and fostering tumour ...
Researchers determine a complex immune infiltrate pattern based on a newly constructed immune map developed using pancreatic cancer cells.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback